Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologi - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmologi - eylea je primerna za odrasle, za zdravljenje:neovascular (mokro) starostna degeneracija rumene pege (amd);vida zaradi degeneracija edem sekundarnega do mrežnice vene (veja rvo ali centralne rvo);vida zaradi diabetično degeneracija edem (dme);vida zaradi kratkovidna choroidal neovascularisation (kratkovidna cnv).

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Evropska unija - slovenščina - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - oftalmologi - visudyne je primerna za zdravljenje:odrasli z exudative (mokro) starostna degeneracija rumene pege (amd) s pretežno klasičnih subfoveal choroidal neovascularisation (cnv) ali;za odrasle z subfoveal choroidal neovascularisation sekundarne patološke kratkovidnost.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanib - mokra makularna degeneracija - oftalmologi - macugen je indicirano za zdravljenje neovaskularne (mokro) starost degeneracije makule (amd).

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna je indiciran za zdravljenje odraslih in pediatričnih bolnikih z izgubo vida zaradi dedne očesne mrežnice distrofija, ki jih povzročajo potrdili biallelic rpe65 mutacije in ki imajo dovolj preživetja celic mrežnice.

Evropska unija - slovenščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - deksametazon - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex je indiciran za zdravljenje odraslih bolnikov z degeneracijo edem naslednje bodisi podružnico mrežnice-vene (brvo) ali centralne mrežnice-vene (crvo). ozurdex je indiciran za zdravljenje odraslih bolnikov z vnetjem zadnji segment očesa, ki predstavljajo, kot noninfectious uveitis. ozurdex je indiciran za zdravljenje odraslih bolnikov s vida zaradi diabetično degeneracija edem (dme), ki so pseudophakic ali, ki so ovrednotena dovolj odziven, ali neprimerne za ne-kortikosteroidne terapije.